Login    Join free Add to favorites    中文
home > news > AMSBIO: Highly Efficient Synthetic mRNAs
Industry Updates | New Products | Supplier News | Upcoming Events | business | web
AMSBIO: Highly Efficient Synthetic mRNAs

hits:1109     Date:10/25/17
AMSBIO announces the launch of a new service for synthesis of custom-designed, highly modified mRNAs prepared by an advantageous in vitro transcription methodology.

Traditional approaches for engineering changes in cellular expression profiles have employed mostly DNA or RNA based viral and non-viral vectors. Unfortunately, these methods carry high risks, due to genomic integration with permanent genetic alteration of cells, and safety and ethical concerns relating to the use of DNA-based vectors in human clinical therapy. Using in vitro synthesized mRNAs offers an advantage if these crucial permanent changes are not needed and the associated problems can be avoided if transient gene expression changes are sufficient or even an advantage.

Until recently concerns about RNA degradation problems have halted widespread use. Recent advances in the availability of synthetic mRNAs (syn-mRNAs) prepared using in vitro transcription methodologies has increased confidence in working with syn-mRNAs.

The AMSBIO custom synthetic mRNA service uses 唯-containing mRNA which is translated more efficiently than its unmodified counterpart, which results in higher protein expression and also reduces the innate antiviral response. The new AMSBIO service includes: synthesis of synthetic DNA, plasmid cloning, purification, full DNA sequencing documentation, PCR amplification of insert, purification and subsequent RNA synthesis by in vitro transcription, purification and characterization. AMSBIO synthetic mRNA is made to research grade for development applications and to GMP grade for cell therapy.

Dr Dusko Ilic, Reader in Stem Cell Science at Kings College London Faculty of Life Sciences & Medicine commented " I am pleased to see AMSBIO are launching an IVT mRNA service". He added "An ideal reprogramming of somatic cells into induced pluripotent stem cells (iPSC) would utilize genome non-integrating vector systems.  Among several available on the market today, I believe that modified synthetic mRNA, as offered by AMSBIO, is the best. It is safe, easy to work with and the reprogramming efficiency is reasonably high. Although the reprogramming protocol with mRNA may seem more laborious than others, it is quite the opposite. The iPSC lines can be used right away - reprogramming and pluripotency marker characterization of single clones can be done in a month, whereas other genome non-integrating vector systems require extensive passaging before the vectors become undetectable and we could start with characterization."

For further information on this new service please visit http://www.amsbio.com/Highly-modified-mRNA.aspx  or contact AMSBIO on 44-1235-828200/ +1-617-945-5033 / info@amsbio.com.

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO can draw upon in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. Widely acknowledged as an expert in cell culture, AMSBIO partners with clients in tailoring cell systems to enhance organoid and spheroid type screening outcomes from a technological and cost-effective perspective.

Worldwide HQ 

AMS Biotechnology (AMSBIO)
184 Milton Park
Abingdon
Oxon OX14 4SE
UK
Tel:+44-1235-828200
Fax:+44-1235-820482
Email:info@amsbio.com
 
North American HQ
 
AMSBIO LLC
1035 Cambridge Street
Cambridge
MA 02141
USA
Tel:+1.617.945.5033 
Tel:+1.800.987.0985 (toll free)
Email:info@amsbio.com
Related News>> more
advertisement

Copyright(C) 2006-2017 Bio-Equip    E-mail:web@bio-equip.cn   娌狪CP澶06040519鍙